CODX - Co-Diagnostics Inc Stock Price, Fair Value and News

$0.36+0.01 (+2.86%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CODX Price Action

Last 7 days

-2.7%

Last 30 days

-10%

Last 90 days

16.1%

Trailing 12 Months

-59.1%

CODX RSI Chart

CODX Valuation

Market Cap

21.9M

Price/Earnings (Trailing)

-0.68

Price/Sales (Trailing)

5.75

EV/EBITDA

-0.33

Price/Free Cashflow

-0.69

CODX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CODX Fundamentals

CODX Revenue

Revenue (TTM)

3.9M

Rev. Growth (Yr)

-77.32%

Rev. Growth (Qtr)

-10.76%

CODX Earnings

Earnings (TTM)

-32.2M

Earnings Growth (Yr)

39.29%

Earnings Growth (Qtr)

23.85%

CODX Profitability

Operating Margin

91.44%

EBT Margin

-851.35%

Return on Equity

-80.8%

Return on Assets

-71.93%

Free Cashflow Yield

-145.11%

CODX Investor Care

Shares Dilution (1Y)

90.71%

Diluted EPS (TTM)

-0.99

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	6.7M	9.1M	7.3M	3.9M
2023	27.4M	20.5M	13.7M	6.8M
2022	100.6M	78.2M	53.2M	34.2M
2021	93.0M	96.3M	104.6M	97.9M
2020	0	0	0	74.6M
2019	0	0	0	0
2018	15.7K	23.8K	31.8K	39.9K
2017	0	0	0	7.7K

Get all data in R, Python etc through our Historical Stock Data APIs

About Co-Diagnostics Inc

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

CEO	Mr. Dwight H. Egan
WEBSITE	codiagnostics.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	145

Co-Diagnostics Inc Frequently Asked Questions

What is the ticker symbol for Co-Diagnostics Inc? What does CODX stand for in stocks?

CODX is the stock ticker symbol of Co-Diagnostics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Co-Diagnostics Inc (CODX)?

As of Wed Dec 03 2025, market cap of Co-Diagnostics Inc is 21.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CODX stock?

You can check CODX's fair value in chart for subscribers.

Is Co-Diagnostics Inc a good stock to buy?

The fair value guage provides a quick view whether CODX is over valued or under valued. Whether Co-Diagnostics Inc is cheap or expensive depends on the assumptions which impact Co-Diagnostics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CODX.

What is Co-Diagnostics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, CODX's PE ratio (Price to Earnings) is -0.68 and Price to Sales (PS) ratio is 5.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CODX PE ratio will change depending on the future growth rate expectations of investors.